ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2023
Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease.
Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Mapping research trends in shared decision-making for type 2 diabetes mellitus: a bibliometric study.Frontiers in health services · 2026Pooled it
- Quality of care for people with chronic kidney disease: a systematic review and meta-analysis.BMJ open · 2025Pooled it
- Oral GLP-1-Based Therapeutics in the Obesity-Metabolic Syndrome-Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Expanding Kidney Care: How Nonphysician Health Workers Can Address the Global CKD Crisis.Kidney international reports · 2026Review
- Preliminary Findings of a Chronic Disease Management Program in Medicare Advantage Enrollees with Mild to Moderate Kidney Disease.International journal of environmental research and public health · 2026Article
- Transformative global models for CKD care: case studies and strategies.Clinical kidney journal · 2026Review
- Addressing Unmet Needs in the Management of Chronic Kidney Disease.International journal of general medicine · 2026Review
- Managing Heart Failure Therapy in Chronic Kidney Disease: Converging Evidence and Ongoing Controversies.Cardiorenal medicine · 2026Article
- Real-World Data as External Control in Assessing the Efficacy of Allogeneic Adipose-Derived Stem Cells Therapy for Advanced Chronic Kidney Disease.Clinical and translational science · 2025Article
- Embedding Implementation Science in Clinical Trials: A Framework for Academic-Life Science Partnerships.Pharmaceutical medicine · 2025Review
- Circulating and Urinary CCL20 in Human Kidney Disease.International journal of molecular sciences · 2025Article
- Article
- Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Patient Perceptions of a Population Health Management Program to Improve Kidney Care: Optimizing care in CKD.Kidney medicine · 2025Article
- Beyond glycemic control: Roles for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney disease.World journal of diabetes · 2025Review
- Population Health Management and Guideline-Concordant Care in CKD: A Secondary Analysis of Kidney Coordinated HeAlth Management Partnership.Journal of the American Society of Nephrology : JASN · 2025Article
- Evaluating the Relationship Between Inertia Levels and Tendency to Medical Errors Among Nurses in Paediatric Clinics.Journal of evaluation in clinical practice · 2025Article
- Integrated primary and secondary care optimizes the management of people with CKD-the LUCID project.Clinical kidney journal · 2025Article
- Assessing patterns of chronic kidney disease care in Australian primary care: a retrospective cohort study of a national general practice dataset.The Lancet regional health. Western Pacific · 2025Article
- Rethinking Models of Chronic Kidney Disease Care: A Narrative Review.Kidney & blood pressure research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
For the first time in many years, guideline-directed drug therapies have emerged that offer substantial cardiorenal benefits, improved quality of life and longevity in patients with chronic kidney disease (CKD) and type 2 diabetes. These treatment options include sodium-glucose cotransporter-2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists and glucagon-like peptide-1 receptor agonists. However, despite compelling evidence from multiple clinical trials, their uptake has been slow in routine clinical practice, reminiscent of the historical evolution of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use. The delay in implementation of these evidence-based therapies highlights the many challenges to optimal CKD care, including: (i) clinical inertia; (ii) low CKD awareness; (iii) suboptimal kidney disease education among patients and providers; (iv) lack of patient and community engagement; (v) multimorbidity and polypharmacy; (vi) challenges in the primary care setting; (vii) fragmented CKD care; (viii) disparities in underserved populations; (ix) lack of public policy focused on health equity; and (x) high drug prices. These barriers to optimal cardiorenal outcomes can be ameliorated by a multifaceted approach, using the Chronic Care Model framework, to include patient and provider education, patient self-management programs, shared decision making, electronic clinical decision support tools, quality improvement initiatives, clear practice guidelines, multidisciplinary and collaborative care, provider accountability, and robust health information technology. It is incumbent on the global kidney community to take on a multidimensional perspective of CKD care by addressing patient-, community-, provider-, healthcare system- and policy-level barriers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.